Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H15BrClFN4O3 |
Molecular Weight | 457.681 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C=NC2=C(F)C(NC3=C(Cl)C=C(Br)C=C3)=C(C=C12)C(=O)NOCCO
InChI
InChIKey=CYOHGALHFOKKQC-UHFFFAOYSA-N
InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)
DescriptionSources: http://adisinsight.springer.com/drugs/800019504Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/17332304
Sources: http://adisinsight.springer.com/drugs/800019504
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/17332304
Selumetinib (AZD6244 or ARRY-142886) is a potent, selective, and ATP-uncompetitive inhibitor of Ras-Raf-mitogen-activated protein kinase kinase (MEK1/2). This inhibition can prevent ERK activation, disrupt downstream signal transduction, and inhibit cancer cell proliferation and survival. Selumetinib has shown tumour suppressive activity in multiple rodent models of human cancer including melanoma, pancreatic, colon, lung, and breast cancers. AstraZeneca is responsible for development and commercialization of selumetinib.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22280975
Curator's Comment: I.p. injection of AZD6244 prevented the development of pain in rats subjected to the chronic constriction injury and reversed already established pain in the spared nerve injury model. No human data available.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3587 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17332304 |
14.0 nM [IC50] | ||
Target ID: CHEMBL2964 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17332304 |
14.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1207 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20179232/ |
75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered: |
SELUMETINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
863 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28019010/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
SELUMETINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
647 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/21519015 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
SELUMETINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6335 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20179232/ |
75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered: |
SELUMETINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2620 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28019010/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
SELUMETINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3299 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/21519015 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
SELUMETINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
5.33 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20179232/ |
75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered: |
SELUMETINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
7.34 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28019010/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
SELUMETINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
10 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/21519015 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
SELUMETINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.4% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28019010/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
SELUMETINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
25 mg/m2 2 times / day steady, oral Recommended Dose: 25 mg/m2, 2 times / day Route: oral Route: steady Dose: 25 mg/m2, 2 times / day Sources: |
unhealthy, 10.2 years (range: 3.5 - 17.4 years) Health Status: unhealthy Age Group: 10.2 years (range: 3.5 - 17.4 years) Sex: M+F Sources: |
Disc. AE: Creatinine increased, Weight increased... AEs leading to discontinuation/dose reduction: Creatinine increased (2%) Sources: Weight increased (2%) Diarrhea (2%) Paronychia (2%) Malignant peripheral nerve sheath tumor (2%) Acute kidney injury (2%) Skin ulcer (2%) |
25 mg/m2 2 times / day steady, oral Recommended Dose: 25 mg/m2, 2 times / day Route: oral Route: steady Dose: 25 mg/m2, 2 times / day Sources: |
unhealthy, 10.2 years (range: 3.5 - 17.4 years) Health Status: unhealthy Age Group: 10.2 years (range: 3.5 - 17.4 years) Sex: M+F Sources: |
Disc. AE: Vomiting, Paronychia... AEs leading to discontinuation/dose reduction: Vomiting (>5) Sources: Paronychia (>5) Diarrhea (>5) Nausea (>5) Abdominal pain (>5) Rash (>5) Skin infection (>5) Influenza like illness (>5) Pyrexia (>5) Weight gain (>5) |
100 mg 2 times / day steady, oral Dose: 100 mg, 2 times / day Route: oral Route: steady Dose: 100 mg, 2 times / day Sources: |
unhealthy, 57.9 years (range: 30-76 years) Health Status: unhealthy Age Group: 57.9 years (range: 30-76 years) Sex: M+F Sources: |
DLT: Acneiform dermatitis, Pleural effusion... Dose limiting toxicities: Acneiform dermatitis (grade 3) Sources: Pleural effusion (grade 3) |
75 mg 2 times / day steady, oral Dose: 75 mg, 2 times / day Route: oral Route: steady Dose: 75 mg, 2 times / day Sources: |
unhealthy, 57.9 years (range: 30-76 years) Health Status: unhealthy Age Group: 57.9 years (range: 30-76 years) Sex: M+F Sources: |
DLT: Fatigue... |
300 mg 2 times / day steady, oral Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy, 58 years (range: 29–78 years) Health Status: unhealthy Age Group: 58 years (range: 29–78 years) Sex: M+F Sources: |
Other AEs: Dermatitis acneiform, Rash... Other AEs: Dermatitis acneiform (grade 3-4, 2 patients) Sources: Rash (grade 3-4, 2 patients) Rash erythematous (grade 3-4, 2 patients) Rash maculo-papular (grade 3-4, 2 patients) Rash pruritic (grade 3-4, 2 patients) Diarrhea (grade 3-4, 1 patient) Nausea (grade 1-2, 3 patients) Fatigue (grade 1-2, 2 patients) Peripheral edema (grade 1-2, 2 patients) Vomiting (grade 1-2, 2 patients) Blurred vision (grade 1-2, 3 patients) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Acute kidney injury | 2% Disc. AE |
25 mg/m2 2 times / day steady, oral Recommended Dose: 25 mg/m2, 2 times / day Route: oral Route: steady Dose: 25 mg/m2, 2 times / day Sources: |
unhealthy, 10.2 years (range: 3.5 - 17.4 years) Health Status: unhealthy Age Group: 10.2 years (range: 3.5 - 17.4 years) Sex: M+F Sources: |
Creatinine increased | 2% Disc. AE |
25 mg/m2 2 times / day steady, oral Recommended Dose: 25 mg/m2, 2 times / day Route: oral Route: steady Dose: 25 mg/m2, 2 times / day Sources: |
unhealthy, 10.2 years (range: 3.5 - 17.4 years) Health Status: unhealthy Age Group: 10.2 years (range: 3.5 - 17.4 years) Sex: M+F Sources: |
Diarrhea | 2% Disc. AE |
25 mg/m2 2 times / day steady, oral Recommended Dose: 25 mg/m2, 2 times / day Route: oral Route: steady Dose: 25 mg/m2, 2 times / day Sources: |
unhealthy, 10.2 years (range: 3.5 - 17.4 years) Health Status: unhealthy Age Group: 10.2 years (range: 3.5 - 17.4 years) Sex: M+F Sources: |
Malignant peripheral nerve sheath tumor | 2% Disc. AE |
25 mg/m2 2 times / day steady, oral Recommended Dose: 25 mg/m2, 2 times / day Route: oral Route: steady Dose: 25 mg/m2, 2 times / day Sources: |
unhealthy, 10.2 years (range: 3.5 - 17.4 years) Health Status: unhealthy Age Group: 10.2 years (range: 3.5 - 17.4 years) Sex: M+F Sources: |
Paronychia | 2% Disc. AE |
25 mg/m2 2 times / day steady, oral Recommended Dose: 25 mg/m2, 2 times / day Route: oral Route: steady Dose: 25 mg/m2, 2 times / day Sources: |
unhealthy, 10.2 years (range: 3.5 - 17.4 years) Health Status: unhealthy Age Group: 10.2 years (range: 3.5 - 17.4 years) Sex: M+F Sources: |
Skin ulcer | 2% Disc. AE |
25 mg/m2 2 times / day steady, oral Recommended Dose: 25 mg/m2, 2 times / day Route: oral Route: steady Dose: 25 mg/m2, 2 times / day Sources: |
unhealthy, 10.2 years (range: 3.5 - 17.4 years) Health Status: unhealthy Age Group: 10.2 years (range: 3.5 - 17.4 years) Sex: M+F Sources: |
Weight increased | 2% Disc. AE |
25 mg/m2 2 times / day steady, oral Recommended Dose: 25 mg/m2, 2 times / day Route: oral Route: steady Dose: 25 mg/m2, 2 times / day Sources: |
unhealthy, 10.2 years (range: 3.5 - 17.4 years) Health Status: unhealthy Age Group: 10.2 years (range: 3.5 - 17.4 years) Sex: M+F Sources: |
Abdominal pain | >5 Disc. AE |
25 mg/m2 2 times / day steady, oral Recommended Dose: 25 mg/m2, 2 times / day Route: oral Route: steady Dose: 25 mg/m2, 2 times / day Sources: |
unhealthy, 10.2 years (range: 3.5 - 17.4 years) Health Status: unhealthy Age Group: 10.2 years (range: 3.5 - 17.4 years) Sex: M+F Sources: |
Diarrhea | >5 Disc. AE |
25 mg/m2 2 times / day steady, oral Recommended Dose: 25 mg/m2, 2 times / day Route: oral Route: steady Dose: 25 mg/m2, 2 times / day Sources: |
unhealthy, 10.2 years (range: 3.5 - 17.4 years) Health Status: unhealthy Age Group: 10.2 years (range: 3.5 - 17.4 years) Sex: M+F Sources: |
Influenza like illness | >5 Disc. AE |
25 mg/m2 2 times / day steady, oral Recommended Dose: 25 mg/m2, 2 times / day Route: oral Route: steady Dose: 25 mg/m2, 2 times / day Sources: |
unhealthy, 10.2 years (range: 3.5 - 17.4 years) Health Status: unhealthy Age Group: 10.2 years (range: 3.5 - 17.4 years) Sex: M+F Sources: |
Nausea | >5 Disc. AE |
25 mg/m2 2 times / day steady, oral Recommended Dose: 25 mg/m2, 2 times / day Route: oral Route: steady Dose: 25 mg/m2, 2 times / day Sources: |
unhealthy, 10.2 years (range: 3.5 - 17.4 years) Health Status: unhealthy Age Group: 10.2 years (range: 3.5 - 17.4 years) Sex: M+F Sources: |
Paronychia | >5 Disc. AE |
25 mg/m2 2 times / day steady, oral Recommended Dose: 25 mg/m2, 2 times / day Route: oral Route: steady Dose: 25 mg/m2, 2 times / day Sources: |
unhealthy, 10.2 years (range: 3.5 - 17.4 years) Health Status: unhealthy Age Group: 10.2 years (range: 3.5 - 17.4 years) Sex: M+F Sources: |
Pyrexia | >5 Disc. AE |
25 mg/m2 2 times / day steady, oral Recommended Dose: 25 mg/m2, 2 times / day Route: oral Route: steady Dose: 25 mg/m2, 2 times / day Sources: |
unhealthy, 10.2 years (range: 3.5 - 17.4 years) Health Status: unhealthy Age Group: 10.2 years (range: 3.5 - 17.4 years) Sex: M+F Sources: |
Rash | >5 Disc. AE |
25 mg/m2 2 times / day steady, oral Recommended Dose: 25 mg/m2, 2 times / day Route: oral Route: steady Dose: 25 mg/m2, 2 times / day Sources: |
unhealthy, 10.2 years (range: 3.5 - 17.4 years) Health Status: unhealthy Age Group: 10.2 years (range: 3.5 - 17.4 years) Sex: M+F Sources: |
Skin infection | >5 Disc. AE |
25 mg/m2 2 times / day steady, oral Recommended Dose: 25 mg/m2, 2 times / day Route: oral Route: steady Dose: 25 mg/m2, 2 times / day Sources: |
unhealthy, 10.2 years (range: 3.5 - 17.4 years) Health Status: unhealthy Age Group: 10.2 years (range: 3.5 - 17.4 years) Sex: M+F Sources: |
Vomiting | >5 Disc. AE |
25 mg/m2 2 times / day steady, oral Recommended Dose: 25 mg/m2, 2 times / day Route: oral Route: steady Dose: 25 mg/m2, 2 times / day Sources: |
unhealthy, 10.2 years (range: 3.5 - 17.4 years) Health Status: unhealthy Age Group: 10.2 years (range: 3.5 - 17.4 years) Sex: M+F Sources: |
Weight gain | >5 Disc. AE |
25 mg/m2 2 times / day steady, oral Recommended Dose: 25 mg/m2, 2 times / day Route: oral Route: steady Dose: 25 mg/m2, 2 times / day Sources: |
unhealthy, 10.2 years (range: 3.5 - 17.4 years) Health Status: unhealthy Age Group: 10.2 years (range: 3.5 - 17.4 years) Sex: M+F Sources: |
Acneiform dermatitis | grade 3 DLT |
100 mg 2 times / day steady, oral Dose: 100 mg, 2 times / day Route: oral Route: steady Dose: 100 mg, 2 times / day Sources: |
unhealthy, 57.9 years (range: 30-76 years) Health Status: unhealthy Age Group: 57.9 years (range: 30-76 years) Sex: M+F Sources: |
Pleural effusion | grade 3 DLT |
100 mg 2 times / day steady, oral Dose: 100 mg, 2 times / day Route: oral Route: steady Dose: 100 mg, 2 times / day Sources: |
unhealthy, 57.9 years (range: 30-76 years) Health Status: unhealthy Age Group: 57.9 years (range: 30-76 years) Sex: M+F Sources: |
Fatigue | grade 3 DLT |
75 mg 2 times / day steady, oral Dose: 75 mg, 2 times / day Route: oral Route: steady Dose: 75 mg, 2 times / day Sources: |
unhealthy, 57.9 years (range: 30-76 years) Health Status: unhealthy Age Group: 57.9 years (range: 30-76 years) Sex: M+F Sources: |
Fatigue | grade 1-2, 2 patients | 300 mg 2 times / day steady, oral Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy, 58 years (range: 29–78 years) Health Status: unhealthy Age Group: 58 years (range: 29–78 years) Sex: M+F Sources: |
Peripheral edema | grade 1-2, 2 patients | 300 mg 2 times / day steady, oral Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy, 58 years (range: 29–78 years) Health Status: unhealthy Age Group: 58 years (range: 29–78 years) Sex: M+F Sources: |
Vomiting | grade 1-2, 2 patients | 300 mg 2 times / day steady, oral Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy, 58 years (range: 29–78 years) Health Status: unhealthy Age Group: 58 years (range: 29–78 years) Sex: M+F Sources: |
Blurred vision | grade 1-2, 3 patients | 300 mg 2 times / day steady, oral Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy, 58 years (range: 29–78 years) Health Status: unhealthy Age Group: 58 years (range: 29–78 years) Sex: M+F Sources: |
Nausea | grade 1-2, 3 patients | 300 mg 2 times / day steady, oral Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy, 58 years (range: 29–78 years) Health Status: unhealthy Age Group: 58 years (range: 29–78 years) Sex: M+F Sources: |
Diarrhea | grade 3-4, 1 patient | 300 mg 2 times / day steady, oral Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy, 58 years (range: 29–78 years) Health Status: unhealthy Age Group: 58 years (range: 29–78 years) Sex: M+F Sources: |
Dermatitis acneiform | grade 3-4, 2 patients | 300 mg 2 times / day steady, oral Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy, 58 years (range: 29–78 years) Health Status: unhealthy Age Group: 58 years (range: 29–78 years) Sex: M+F Sources: |
Rash erythematous | grade 3-4, 2 patients | 300 mg 2 times / day steady, oral Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy, 58 years (range: 29–78 years) Health Status: unhealthy Age Group: 58 years (range: 29–78 years) Sex: M+F Sources: |
Rash maculo-papular | grade 3-4, 2 patients | 300 mg 2 times / day steady, oral Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy, 58 years (range: 29–78 years) Health Status: unhealthy Age Group: 58 years (range: 29–78 years) Sex: M+F Sources: |
Rash pruritic | grade 3-4, 2 patients | 300 mg 2 times / day steady, oral Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy, 58 years (range: 29–78 years) Health Status: unhealthy Age Group: 58 years (range: 29–78 years) Sex: M+F Sources: |
Rash | grade 3-4, 2 patients | 300 mg 2 times / day steady, oral Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: |
unhealthy, 58 years (range: 29–78 years) Health Status: unhealthy Age Group: 58 years (range: 29–78 years) Sex: M+F Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Drug as victim
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213756Orig1s000MultidisciplineR.pdf Page: 50.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. | 2010 Nov 24 |
|
Comprehensive analysis of kinase inhibitor selectivity. | 2011 Oct 30 |
|
Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. | 2012 Jul |
|
MEK and the inhibitors: from bench to bedside. | 2013 Apr 12 |
|
Flavanoids induce expression of the suppressor of cytokine signalling 3 (SOCS3) gene and suppress IL-6-activated signal transducer and activator of transcription 3 (STAT3) activation in vascular endothelial cells. | 2013 Sep 1 |
|
Synergistic induction of human cathelicidin antimicrobial peptide gene expression by vitamin D and stilbenoids. | 2014 Mar |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://adisinsight.springer.com/drugs/800019504
Oral selumetinib (50, 100 and 200mg bid for 28-day cycles) was well tolerated in patients with refractory solid tumours. The maximum tolerated dose was established to be 200mg bid. 100 mg dose of selumetinib proved to be more tolerable than the 200mg dose over prolonged periods. The 100mg dose has been chosen for phase II studies.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17699718
The sensitivity of a large panel of cell lines to Selumetinib (AZD6244 or ARRY-142886) was evaluated in vitro and correlated with RAS and BRAF gene mutation status. There was a wide range of sensitivity to AZD6244 from highly sensitive (IC50, <100 nmol/L) to highly resistant (>10 μmol/L)
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EU-Orphan Drug |
EU/3/18/2050
Created by
admin on Mon Mar 31 18:26:39 GMT 2025 , Edited by admin on Mon Mar 31 18:26:39 GMT 2025
|
||
|
NCI_THESAURUS |
C69145
Created by
admin on Mon Mar 31 18:26:39 GMT 2025 , Edited by admin on Mon Mar 31 18:26:39 GMT 2025
|
||
|
NCI_THESAURUS |
C129825
Created by
admin on Mon Mar 31 18:26:39 GMT 2025 , Edited by admin on Mon Mar 31 18:26:39 GMT 2025
|
||
|
FDA ORPHAN DRUG |
475815
Created by
admin on Mon Mar 31 18:26:39 GMT 2025 , Edited by admin on Mon Mar 31 18:26:39 GMT 2025
|
||
|
FDA ORPHAN DRUG |
624017
Created by
admin on Mon Mar 31 18:26:39 GMT 2025 , Edited by admin on Mon Mar 31 18:26:39 GMT 2025
|
||
|
FDA ORPHAN DRUG |
471015
Created by
admin on Mon Mar 31 18:26:39 GMT 2025 , Edited by admin on Mon Mar 31 18:26:39 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2289380
Created by
admin on Mon Mar 31 18:26:39 GMT 2025 , Edited by admin on Mon Mar 31 18:26:39 GMT 2025
|
PRIMARY | |||
|
9078
Created by
admin on Mon Mar 31 18:26:39 GMT 2025 , Edited by admin on Mon Mar 31 18:26:39 GMT 2025
|
PRIMARY | |||
|
DTXSID3048944
Created by
admin on Mon Mar 31 18:26:39 GMT 2025 , Edited by admin on Mon Mar 31 18:26:39 GMT 2025
|
PRIMARY | |||
|
100000124313
Created by
admin on Mon Mar 31 18:26:39 GMT 2025 , Edited by admin on Mon Mar 31 18:26:39 GMT 2025
|
PRIMARY | |||
|
606143-52-6
Created by
admin on Mon Mar 31 18:26:39 GMT 2025 , Edited by admin on Mon Mar 31 18:26:39 GMT 2025
|
PRIMARY | |||
|
5388
Created by
admin on Mon Mar 31 18:26:39 GMT 2025 , Edited by admin on Mon Mar 31 18:26:39 GMT 2025
|
PRIMARY | |||
|
C66939
Created by
admin on Mon Mar 31 18:26:39 GMT 2025 , Edited by admin on Mon Mar 31 18:26:39 GMT 2025
|
PRIMARY | |||
|
6UH91I579U
Created by
admin on Mon Mar 31 18:26:39 GMT 2025 , Edited by admin on Mon Mar 31 18:26:39 GMT 2025
|
PRIMARY | |||
|
XX-36
Created by
admin on Mon Mar 31 18:26:39 GMT 2025 , Edited by admin on Mon Mar 31 18:26:39 GMT 2025
|
PRIMARY | |||
|
m12218
Created by
admin on Mon Mar 31 18:26:39 GMT 2025 , Edited by admin on Mon Mar 31 18:26:39 GMT 2025
|
PRIMARY | |||
|
SELUMETINIB
Created by
admin on Mon Mar 31 18:26:39 GMT 2025 , Edited by admin on Mon Mar 31 18:26:39 GMT 2025
|
PRIMARY | |||
|
90227
Created by
admin on Mon Mar 31 18:26:39 GMT 2025 , Edited by admin on Mon Mar 31 18:26:39 GMT 2025
|
PRIMARY | |||
|
6UH91I579U
Created by
admin on Mon Mar 31 18:26:39 GMT 2025 , Edited by admin on Mon Mar 31 18:26:39 GMT 2025
|
PRIMARY | |||
|
10127622
Created by
admin on Mon Mar 31 18:26:39 GMT 2025 , Edited by admin on Mon Mar 31 18:26:39 GMT 2025
|
PRIMARY | |||
|
DB11689
Created by
admin on Mon Mar 31 18:26:39 GMT 2025 , Edited by admin on Mon Mar 31 18:26:39 GMT 2025
|
PRIMARY | |||
|
CHEMBL1614701
Created by
admin on Mon Mar 31 18:26:39 GMT 2025 , Edited by admin on Mon Mar 31 18:26:39 GMT 2025
|
PRIMARY | |||
|
SUB32237
Created by
admin on Mon Mar 31 18:26:39 GMT 2025 , Edited by admin on Mon Mar 31 18:26:39 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE ACTIVE (PARENT)
SALT/SOLVATE (PARENT)